

# Clinical Trial Design in the Era of Genomic Medicine

Research Advocacy Network  
Symposium for Advocates  
Dallas Texas November 20-22, 2013

Connie Szczepanek, RN, BSN  
Patrick Gavin R.Ph.  
Grand Rapids Clinical Oncology Program

---

---

---

---

---

---

---

---

## Conflict of Interest Statement

We have no conflicts of interest to disclose

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---



### Grand Rapids Clinical Oncology Program *A Consortium Approach*


Funded by a National Cancer Institute CCOP Grant since 1983 and the following

**Consortium Members**

- 1 Bronson Battle Creek
- 2 Mercy Health Muskegon
- 3 Mercy Health Saint Mary's
- 4 Michigan State University College of Human Medicine
- 5 Munson Medical Center
- 6 Spectrum Health Hospitals
- 7 Spectrum Health Reed City
- 8 Van Andel Research Institute
- 9 West Michigan Cancer Center

**Affiliate Member**

- 10 Spectrum Health Big Rapids Hospital




---

---

---

---

---

---

---

---

---

---

---

---

### Patient Advisory Board for Clinical Research

Established May 2008




Grand Rapids Clinical Oncology Program  
Committed to Community, Cancer Research, and Education

---

---

---

---

---

---

---

---

---

---

---

---

### Cancer Clinical Trials...



WE HAVE  
Real Answers, Real Options, Real Miracles  
Right here in our community!

*...Hope for the Future*

*Grand Rapids Clinical Oncology Program (CCOP)*

---

---

---

---

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- Historical view of clinical trials
  - Very few drugs to choose from
  - Terrible side effect profiles
    - We didn't have much to help
  - What we had didn't work very well

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- Trials in the 1990s and early 2000
  - Almost an explosive number of new drugs
  - Much stronger emphasis on helping patients deal with the side effects of the drugs
  - Roll out of many large Phase III trials
  - We saw significant improvement in survival rates of many cancers
    - Leukemia
    - Breast
    - Prostate

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- What is happening today?
  - Drugs are getting to be more patients specific
  - Everything is about DNA
  - Movement from many large Phase III trials to smaller and more focuses phase II trials
  - Patients have moved from being "subjects" to a more involved role of "participant"
  - Patient Reported Outcomes (PROs) and Quality of Life Assessment now becoming more of the norm rather than the exception.

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- Tomorrow-The economics of Healthcare
  - How will we fund everything we need to do in the community?
  - How can we make this affordable for the patient?
  - How do we communicate to patients?
    - Revised Informed Consent documents
    - Required publishing of all study results
    - Plain language summaries

---

---

---

---

---

---

---

---

**Real answers, real options, and  
real miracles ....  
here in our community!**

11

---

---

---

---


---

---

---

---

**Patients adding value**



---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- How can the Cooperative Group advocates help us?
- 1. Standardization
  - There are no standards between cooperative groups today (forms, formats reports, descriptions)
  - A common look for trial info would help patients as they do their search on clinical trials.gov etc

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- 2. Patient friendly concept information
  - A. What is the trial about?
  - B. What do I need to do to qualify?
  - C. What will be expected of me if I participate? (biopsies, scans etc)
  - D. What should I ask my doctor?
  - E. What will we learn in this trial
  - F. Plain language summaries (yea for Deb Collyar!)

---

---

---

---

---

---

---

---

## ***Clinical Trial Design in the Era of Genomic Medicine***

- 3. Patient directed "educational material"
  - IRB ready
  - Handouts for cancer centers, doctors offices, patient gathering replaces
  - Social Media ready information to be posted by trial sites or support groups
  - Pre-written email solicitations

---

---

---

---

---

---

---

---

## Clinical Trial Design in the Era of Genomic Medicine

- 4. A meaningful Accrual Plan
  - Research advocates should be asking questions about the ability of this trial to hit required accrual numbers.
  - Pat's favorite questions to P.I.s
    - "Why would my doctor recommend I participate in this trial?"
    - Why should I participate?
  - Identify why patients won't participate
    - Randomization, invasive tests etc.

---

---

---

---

---

---

---

---

## Outreach to Patients

[www.grcop.org](http://www.grcop.org)  
<http://www.lymphomation.org/>  
[www.cisncancer.org](http://www.cisncancer.org)  
[www.allianceforclinicaltrials.inoncology.org](http://www.allianceforclinicaltrials.inoncology.org)

---

---

---

---

---

---

---

---




---

---

---

---

---

---

---

---